148 related articles for article (PubMed ID: 22391727)
1. 18F-DOPA PET/CT in neuroblastoma: comparison of conventional imaging with CT/MR.
Lopci E; Piccardo A; Nanni C; Altrinetti V; Garaventa A; Pession A; Cistaro A; Chiti A; Villavecchia G; Fanti S
Clin Nucl Med; 2012 Apr; 37(4):e73-8. PubMed ID: 22391727
[TBL] [Abstract][Full Text] [Related]
2. Comparison of 18F-dopa PET/CT and 123I-MIBG scintigraphy in stage 3 and 4 neuroblastoma: a pilot study.
Piccardo A; Lopci E; Conte M; Garaventa A; Foppiani L; Altrinetti V; Nanni C; Bianchi P; Cistaro A; Sorrentino S; Cabria M; Pession A; Puntoni M; Villavecchia G; Fanti S
Eur J Nucl Med Mol Imaging; 2012 Jan; 39(1):57-71. PubMed ID: 21932116
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic value of 18F-FDG PET/CT in paediatric neuroblastoma: comparison with 131I-MIBG scintigraphy.
Dhull VS; Sharma P; Patel C; Kundu P; Agarwala S; Bakhshi S; Bhatnagar V; Bal C; Kumar R
Nucl Med Commun; 2015 Oct; 36(10):1007-13. PubMed ID: 26049371
[TBL] [Abstract][Full Text] [Related]
4. Role of 18F-dopa PET/CT imaging in the management of patients with 111In-pentetreotide negative GEP tumours.
Ambrosini V; Tomassetti P; Rubello D; Campana D; Nanni C; Castellucci P; Farsad M; Montini G; Al-Nahhas A; Franchi R; Fanti S
Nucl Med Commun; 2007 Jun; 28(6):473-7. PubMed ID: 17460538
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of ¹⁸F-DOPA PET/CT at the time of recurrence in patients affected by neuroblastoma.
Piccardo A; Puntoni M; Lopci E; Conte M; Foppiani L; Sorrentino S; Morana G; Naseri M; Cistaro A; Villavecchia G; Fanti S; Garaventa A
Eur J Nucl Med Mol Imaging; 2014 Jun; 41(6):1046-56. PubMed ID: 24562643
[TBL] [Abstract][Full Text] [Related]
6. Ability of (18)F-DOPA PET/CT and fused (18)F-DOPA PET/MRI to assess striatal involvement in paediatric glioma.
Morana G; Puntoni M; Garrè ML; Massollo M; Lopci E; Naseri M; Severino M; Tortora D; Rossi A; Piccardo A
Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1664-72. PubMed ID: 26911489
[TBL] [Abstract][Full Text] [Related]
7. 6-[F-18]Fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to conventional imaging with (123)I-metaiodobenzylguanidine scintigraphy, computer tomography, and magnetic resonance imaging in localizing tumors causing catecholamine excess.
Fiebrich HB; Brouwers AH; Kerstens MN; Pijl ME; Kema IP; de Jong JR; Jager PL; Elsinga PH; Dierckx RA; van der Wal JE; Sluiter WJ; de Vries EG; Links TP
J Clin Endocrinol Metab; 2009 Oct; 94(10):3922-30. PubMed ID: 19622618
[TBL] [Abstract][Full Text] [Related]
8. Comparison of 123I-MIBG SPECT-CT and 18F-DOPA PET-CT in the evaluation of patients with known or suspected recurrent paraganglioma.
Rufini V; Treglia G; Castaldi P; Perotti G; Calcagni ML; Corsello SM; Galli G; Fanti S; Giordano A
Nucl Med Commun; 2011 Jul; 32(7):575-82. PubMed ID: 21471850
[TBL] [Abstract][Full Text] [Related]
9. Value of combined 6-[18F]fluorodihydroxyphenylalanine PET/CT for imaging of neuroendocrine tumours.
Schiesser M; Veit-Haibach P; Muller MK; Weber M; Bauerfeind P; Hany T; Clavien PA
Br J Surg; 2010 May; 97(5):691-7. PubMed ID: 20225244
[TBL] [Abstract][Full Text] [Related]
10. Diagnosis, Treatment Response, and Prognosis: The Role of
Piccardo A; Morana G; Puntoni M; Campora S; Sorrentino S; Zucchetta P; Ugolini M; Conte M; Cistaro A; Ferrarazzo G; Pescetto M; Lattuada M; Bottoni G; Garaventa A; Giovanella L; Lopci E
J Nucl Med; 2020 Mar; 61(3):367-374. PubMed ID: 31541036
[TBL] [Abstract][Full Text] [Related]
11. Bone and lymph node metastases from neuroblastoma detected by 18F-DOPA-PET/CT and confirmed by posttherapy 131I-MIBG but negative on diagnostic 123I-MIBG scan.
Piccardo A; Lopci E; Conte M; Cabria M; Cistaro A; Garaventa A; Villavecchia G
Clin Nucl Med; 2014 Jan; 39(1):e80-3. PubMed ID: 23579975
[TBL] [Abstract][Full Text] [Related]
12. Value of 18F-3,4-dihydroxyphenylalanine PET/MR image fusion in pediatric supratentorial infiltrative astrocytomas: a prospective pilot study.
Morana G; Piccardo A; Milanaccio C; Puntoni M; Nozza P; Cama A; Zefiro D; Cabria M; Rossi A; Garrè ML
J Nucl Med; 2014 May; 55(5):718-23. PubMed ID: 24652828
[TBL] [Abstract][Full Text] [Related]
13. 18F-DOPA PET/CT biodistribution consideration in 107 consecutive patients with neuroendocrine tumours.
Chondrogiannis S; Grassetto G; Marzola MC; Rampin L; Massaro A; Bellan E; Ferretti A; Mazza A; Al-Nahhas A; Rubello D
Nucl Med Commun; 2012 Feb; 33(2):179-84. PubMed ID: 22083098
[TBL] [Abstract][Full Text] [Related]
14. (18)F-DOPA PET/CT and MRI: description of 12 histologically-verified pheochromocytomas.
Magnaldi S; Mayerhoefer ME; Khameneh A; Schuetz M; Javor D; Mitterhauser M; Dudczak R; Hacker M; Karanikas G
Anticancer Res; 2014 Feb; 34(2):791-5. PubMed ID: 24511014
[TBL] [Abstract][Full Text] [Related]
15. Role of 18F-DOPA PET/CT in diagnosis and follow-up of adrenal and extra-adrenal paragangliomas.
Bacca A; Chiacchio S; Zampa V; Carrara D; Duce V; Congregati C; Simi P; Taddei S; Materazzi G; Volterrani D; Mariani G; Bernini G
Clin Nucl Med; 2014 Jan; 39(1):14-20. PubMed ID: 24300347
[TBL] [Abstract][Full Text] [Related]
16. Assessment of multifocality and axillary nodal involvement in early-stage breast cancer patients using 18F-FDG PET/CT compared to contrast-enhanced and diffusion-weighted magnetic resonance imaging and sentinel node biopsy.
Ergul N; Kadioglu H; Yildiz S; Yucel SB; Gucin Z; Erdogan EB; Aydin M; Muslumanoglu M
Acta Radiol; 2015 Aug; 56(8):917-23. PubMed ID: 25013091
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic performance of 18F-dihydroxyphenylalanine positron emission tomography in patients with paraganglioma: a meta-analysis.
Treglia G; Cocciolillo F; de Waure C; Di Nardo F; Gualano MR; Castaldi P; Rufini V; Giordano A
Eur J Nucl Med Mol Imaging; 2012 Jul; 39(7):1144-53. PubMed ID: 22358431
[TBL] [Abstract][Full Text] [Related]
18. Comparison of (68)Ga-DOTA-Tyr(3)-octreotide and (18)F-fluoro-L-dihydroxyphenylalanine positron emission tomography in neuroendocrine tumor patients.
Putzer D; Gabriel M; Kendler D; Henninger B; Knoflach M; Kroiss A; Vonguggenberg E; Warwitz B; Virgolini IJ
Q J Nucl Med Mol Imaging; 2010 Feb; 54(1):68-75. PubMed ID: 20168288
[TBL] [Abstract][Full Text] [Related]
19. Complementary roles of 18F-DOPA PET/CT and 18F-FDG PET/CT in medullary thyroid cancer.
Kauhanen S; Schalin-Jäntti C; Seppänen M; Kajander S; Virtanen S; Schildt J; Lisinen I; Ahonen A; Heiskanen I; Väisänen M; Arola J; Korsoff P; Ebeling T; Sane T; Minn H; Välimäki MJ; Nuutila P
J Nucl Med; 2011 Dec; 52(12):1855-63. PubMed ID: 22052128
[TBL] [Abstract][Full Text] [Related]
20. Clinical value of 18-fluorine-fluorodihydroxyphenylalanine positron emission tomography/computed tomography in the follow-up of medullary thyroid carcinoma.
Luster M; Karges W; Zeich K; Pauls S; Verburg FA; Dralle H; Glatting G; Buck AK; Solbach C; Neumaier B; Reske SN; Mottaghy FM
Thyroid; 2010 May; 20(5):527-33. PubMed ID: 20450432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]